Clayton K. Oakley

Dec 5, 2024 | cancernetwork.com | Robin R. High |Apar Kishor Ganti |Alissa Marr |Clayton K. Oakley |Amulya Yellala |Sunil Tulpule

December 5, 2024By OncologyONCOLOGY Vol 38, Issue 12Pages: 462-468These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens. AbstractIntroduction: There are limited data available regarding patient outcomes in those who would have been ineligible to receive therapy based on the original clinical trial eligibility criteria.